China’s Next Phase in Biopharma

In May 2025, Porsche Consulting argued that China had moved beyond the role of a fast follower and emerged as a genuine innovator in biopharma.¹  While executives broadly agreed with that trajectory, many still treated it as something to observe rather than act upon. Twelve months later, that stance is no longer viable. Western pharma leaders continue to underestimate both the extent of their dependence on China and the urgency of actively managing it. The country is no longer merely a production base; it simultaneously serves as a manufacturing hub (with roughly 79 percent of U.S. biotech firms relying on China-based contract manufacturers²), a source of innovation (around one-third of all newly out-licensed molecules now originate there³), and a fast-growing consumption market of 1.4 billion people. This structural reliance has deepened more rapidly than many leadership teams, and their boards, have fully recognized.

This pattern is not unfamiliar. Biopharma leaders risk repeating similar misjudgments as other industries: recognizing the trend while underestimating its speed and structural depth. And unlike other industries, biopharma dependencies compound even faster, across research, clinical development, and manufacturing, making them far harder to unwind.

China undergoes a structural shift with a long planning horizon

Recent developments underscore the shift. Outbound licensing by Chinese biotech firms reached a record $135.7 billion in 2025, nearly three times the level of a year earlier, and the first quarter of 2026 added a further $60 billion, projected to hit $240 billion by year end.³

China’s 15th Five-Year Plan formally elevated biotechnology to a strategic national priority.^{4; 5} Big Pharma, which only a year ago was still debating the scale of its China engagement, has since responded with tangible capital: AstraZeneca committed $15 billion through 2030, alongside a multi-billion commitment from Eli Lilly and further significant plans involving Novartis and Sanofi. The broader context has also evolved, with governments increasingly treating healthcare as critical infrastructure, comparable to energy or defense, and redefining policy in the U.S., Europe, and China alike.⁶

Three poles, three trajectories, and why the velocity differs

While that broader backdrop is important, the real center of gravity lies elsewhere. The United States retains leadership in frontier science, venture-capital depth, and regulatory credibility, yet it is generating its own headwinds through pricing pressure, reshoring agendas, and supply-chain uncertainty. Europe still benefits from strong institutions and talent, but its system prioritizes stability over speed, capital concentration, and industrial scaling. China, by contrast, is emerging as the most effective environment for industrializing biopharma innovation at scale.

Porsche Consulting’s own analysis of facility investment makes the divergence concrete.⁷ Mapping the announced capital expenditure of the world’s twenty largest pharma companies from 2024 to date reveals a striking gap between headline and execution. The United States dominates on announced volume, with more than $460 billion pledged, yet only about 13% of that capital is tied to a specific site with a disclosed amount and timeline. The remainder is programmatic: broad, multi-year commitments, often announced in response to tariff and pricing pressure, whose execution remains uncertain. China’s picture is the inverse. Of roughly $24 billion in announced investment, about 65% is already tied to named sites with clear timelines and local regulatory logic. In absolute terms, China’s execution-ready capital now stands at nearly twice Europe’s, and in 2026 it overtook U.S. site-specific investment outright. Europe, meanwhile, has stalled: 2024 activity gave way to a 2025 slowdown and, in 2026, outright reversal, as Eli Lilly and Boehringer Ingelheim withdrew billions in planned German investment over pricing reforms.⁸

For Western companies, the central question has therefore shifted. Engagement with China is no longer optional; what matters is whether it is being managed as deliberately as the numbers demand.

A system designed for advantage, not just speed

Focusing solely on speed, however, misses the point. China’s real differentiator lies in the deliberate design of its system at national scale. The 15th Five-Year Plan does not represent a break from previous policy but rather sharpens a long-standing direction from capacity expansion toward quality, resilience, and strategic positioning. National priorities cascade into provincial and municipal incentives, aligning capital deployment with clear expectations around localization, clinical trials, technology transfer, and long-term commitment. Companies entering China do not simply explore abstract opportunities; they build tangible capabilities and these accumulate concretely over time. 

This becomes visible in ecosystem density. In hubs such as Beijing, Shanghai, and Shenzhen, alongside emerging clusters like Hangzhou and Suzhou, the entire innovation value chain, universities, hospitals, CROs, CDMOs, regulators, and capital, is concentrated within a single geography, reducing friction at every stage. For global pharma under productivity pressure, this creates a form of innovation arbitrage: faster cycles, lower costs, and earlier de-risking without compromising rigor.  The impact is most pronounced in clinical development, where China now runs more trials than any other country.⁹ In this, large, treatment-naïve patient populations, particularly in oncology, can benefit from access to trials, concomitantly accelerating enrollment and proof-of-concept timelines for the PharmaCos running them. 

China’s modality landscape should likewise be read less as a gap than as deliberate concentration. The country has built real depth in ADCs, monoclonal antibodies, RNAi therapeutics, biosimilars, and cell-therapy processes. It has yet to achieve full dominance in advanced frontier platforms, such as next-generation genome editing, de novo protein design, or foundational AI architectures, but the gap is narrowing, and the duration of that window is one of the defining strategic questions of the coming five years. In manufacturing, the critical factor is not cost but the accumulation of learning curves: each production run, regulatory filing, and scale-up challenge solved within China’s ecosystem builds process expertise that is difficult to replicate elsewhere.

Reimbursement reinforces the advantage. Often viewed as a pricing tool, it functions in practice as industrial policy. The interplay of regulatory approval, NRDL inclusion, volume-based procurement, and payment reform creates a dual-speed market: intense pressure on undifferentiated products, but accelerated pathways for genuinely innovative ones. Rather than penalizing innovation, the system discourages incrementalism. As a result, China increasingly combines consumption scale, production depth, and a powerful innovation engine in a way few markets can match.

The real risk lies not in exposure, but in unmanaged dependence

The next 12 to 24 months will largely determine how quickly strategic flexibility diminishes. The execution of the 15th Five-Year Plan will define how cluster incentives, data-localization requirements, and market-access rules unfold in practice. At the same time, debates in the United States around supply-chain security are raising board-level awareness of dependency without necessarily reducing it, and current policy uncertainty may even deepen exposure to China rather than unwind it.

This is why the perceived optionality of China exposure must be questioned. Many leadership teams still assume they can adjust their engagement over time. In reality, that flexibility is often more limited than it appears. Clinical programs dependent on Chinese patient recruitment are difficult to relocate without delay. Manufacturing processes developed with Chinese CDMOs embed expertise that cannot be easily transferred. Pipelines built around China-origin assets constrain sourcing flexibility more than anticipated. The underlying risk is not exposure itself, but exposure that has not been consciously designed. A useful test is whether leadership can clearly distinguish where China is essential, where it is substitutable, and where it is intentionally excluded.

The strategic response is neither disengagement nor passive continuation; it requires deliberate choice. China should be reframed not only as a commercial market but as a driver of capabilities, from clinical speed to manufacturing expertise and early-stage innovation. Companies must define explicitly which activities belong within China and which do not, whether for intellectual property, data-sovereignty, ethical, or geopolitical reasons. Localization should follow learning-curve logic rather than cost alone, and the sourcing of Chinese assets demands rigorous diligence. Ultimately, the resulting interdependence must be governed at the appropriate level, with clear board oversight, defined triggers, and robust guardrails.

Success will not favor those reacting most quickly to headlines, nor those clinging to an outdated model of globalization. It will depend on the ability to design a deliberate global footprint, assign distinct roles to each innovation hub, and act before those roles solidify into constraints.